As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

 1/25/24  Orbimed Advisors LLC              SC 13D/A               2:134K Edgewise Therapeutics, Inc.       Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
          OrbiMed Genesis GP LLC³
 9/21/23  Orbimed Advisors LLC              SC 13D/A               2:148K Ikena Oncology, Inc.              Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
          OrbiMed Genesis GP LLC³
 9/14/23  Orbimed Advisors LLC              SC 13D/A               2:145K Ikena Oncology, Inc.              Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
          OrbiMed Genesis GP LLC³
 5/24/23  Orbimed Advisors LLC              SC 13D/A               2:119K Prelude Therapeutics Inc.         Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
12/27/22  Orbimed Advisors LLC              SC 13D/A               2:109K Oric Pharmaceuticals, Inc.        Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
12/27/22  Orbimed Advisors LLC              SC 13D/A               2:110K Verona Pharma plc                 Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
11/30/22  Orbimed Advisors LLC              SC 13D/A               2:114K ARS Pharmaceuticals, Inc.         Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
 9/16/22  Orbimed Advisors LLC              SC 13D/A               3:173K Edgewise Therapeutics, Inc.       Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
          OrbiMed Genesis GP LLC³
 8/12/22  Orbimed Advisors LLC              SC 13D/A               2:108K Verona Pharma plc                 Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
10/14/21  Orbimed Advisors LLC              SC 13G/A               2:73K  KALA BIO, Inc.                    Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
 8/16/21  Orbimed Advisors LLC              SC 13D/A               2:129K Ikena Oncology, Inc.              Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
          OrbiMed Genesis GP LLC³
 8/12/21  Orbimed Advisors LLC              SC 13D/A               2:111K Oric Pharmaceuticals, Inc.        Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
 4/15/21‡ Orbimed Advisors LLC              SC 13D      4/14/21    2:142K Ikena Oncology, Inc.              Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
          OrbiMed Genesis GP LLC³
  4/8/21‡ Orbimed Advisors LLC              SC 13D       4/7/21    2:142K Edgewise Therapeutics, Inc.       Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
          OrbiMed Genesis GP LLC³
  4/7/21  Orbimed Advisors LLC              SC 13D/A               2:134K Turning Point Therapeutics, Inc.  Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
 3/26/21  Orbimed Advisors LLC              SC 13D/A               2:123K CalciMedica, Inc.                 Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
 3/22/21‡ Orbimed Advisors LLC              SC 13D/A    3/19/21    2:123K Oric Pharmaceuticals, Inc.        Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
  3/2/21‡ Orbimed Advisors LLC              SC 13G/A     3/1/21    2:80K  KALA BIO, Inc.                    Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
 2/12/21  Orbimed Advisors LLC              SC 13G/A               2:86K  KALA BIO, Inc.                    Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³
 1/14/21‡ Orbimed Advisors LLC              SC 13D/A    1/13/21    3:154K Prelude Therapeutics Inc.         Shearman & Sterling LLP  
          OrbiMed Capital GP VI LLC³
          Orbimed Capital LLC³

____________
‡	A non-Insider-Ownership Filing that was accepted after the SEC “closed” at 5:30:00pm ET.  The legal “Filed As Of” date may be the next, or another, day.
¹	Filing/Form Types:  -K
	SC 13D	Statement of Acquisition of Beneficial Ownership by an “Active” Investor — Schedule 13D.
	SC 13G	Statement of Acquisition of Beneficial Ownership by a “Passive” Investor — Schedule 13G.
	/A	Amendment to, or Amended version of, a previous Filing of this Type.
³	Group Member:  A Registrant or non-Registrant party to this Filing made by a Group.